Sintilimab plus bevacizumab followed by resection in intermediate-stage hepatocellular carcinoma: a phase Ib clinical trial with biomarker analysis

Sintilimab plus bevacizumab followed by resection in intermediate-stage hepatocellular carcinoma: a phase Ib clinical trial with biomarker analysis

Objective This phase Ib trial aimed to assess the safety and efficacy of sintilimab plus bevacizumab (sintilimab/bev), followed by resection in patients with potentially resectable intermediate-stage hepatocellular carcinoma (HCC) and explore the clinical implications of circulating tumour DNA (ctDN...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jia Fan, Shuang-Jian Qiu, Xiao-Ying Wang, Qiang Gao, Ying-Hong Shi, Yuan Ji, Cheng Huang, Hui-Chuan Sun, Xiao-Dong Zhu, Zi-Yi Wang, Ying-Hao Shen
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2024-12-01
Series:	BMJ Oncology
Online Access:	https://bmjoncology.bmj.com/content/3/1/e000578.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Matching-adjusted indirect comparison of tislelizumab plus lenvatinib versus sintilimab plus bevacizumab biosimilar as first-line treatment for unresectable hepatocellular carcinoma
by: Kunyuan Wang, et al.
Published: (2025-06-01)

Predictors of recurrence after conversion therapy in unresectable hepatocellular carcinoma treated with HAIC, bevacizumab, and sintilimab
by: Chang-Fu Liu, et al.
Published: (2025-08-01)

Prognostic Biomarkers for Hepatocellular Carcinoma Patients Treated With Atezolizumab plus Bevacizumab Combination Therapy
by: Long-Bin Jeng MD, et al.
Published: (2025-04-01)

Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study
by: Lingzhan Meng, et al.
Published: (2024-11-01)

Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma
by: Binghua Li, et al.
Published: (2025-01-01)

Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment
by: Young Eun Chon, et al.
Published: (2023-02-01)

The safety and effectiveness of sintilimab versus camrelizumab, both plus targeted drugs, in advanced hepatocellular carcinoma
by: Chenglong Zhao, et al.
Published: (2025-06-01)

Efficacy and safety of sintilimab plus bevacizumab and CAPOX as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer
by: Yanrong Wang, et al.
Published: (2025-03-01)

Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial
by: Chuanhua Zhao, et al.
Published: (2025-08-01)

Sintilimab plus lenvatinib in combination with transarterial chemoembolization and subsequent radiofrequency ablation for unresectable hepatocellular carcinoma: a single-arm, single-center study
by: Xiaochun Chen, et al.
Published: (2025-07-01)

Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment
by: F. Rossari, et al.
Published: (2025-06-01)

Lenvatinib plus Pembrolizumab Combined with Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma
by: Masatoshi Kudo
Published: (2025-01-01)

Safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria
by: Lei Yu, et al.
Published: (2025-01-01)

Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: the first-in-human phase Ia/Ib study
by: Chenyu Mao, et al.
Published: (2024-12-01)

Letter to the editor: safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria
by: Bi-Cheng Wang
Published: (2025-03-01)

Reply to correspondence on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
by: Hiroaki Kanzaki, et al.
Published: (2025-01-01)

Correspondence to letter to the editor on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
by: Sung Hwan Lee, et al.
Published: (2025-01-01)

Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial”
by: Sung Hwan Lee, et al.
Published: (2025-01-01)

Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis
by: Hongfu Cai, et al.
Published: (2024-10-01)

Updated overall survival data and predictive biomarkers of autologous NK cells plus Sintilimab as second-line treatment for advanced non-small cell lung cancer
by: Lin Jia, et al.
Published: (2025-05-01)

Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trial
by: Jingjing Li, et al.
Published: (2025-07-01)

Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts
by: Daniela A Bota, et al.
Published: (2018-07-01)

Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
by: Naoshi Nishida
Published: (2025-01-01)

Adjuvant immunotherapy improves survival in completely resected stage IB–III NSCLC: a systematic review and meta-analysis
by: Hong Huang, et al.
Published: (2025-04-01)

Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
by: Hiroaki Kanzaki, et al.
Published: (2025-01-01)

Fruquintinib and sintilimab plus SOX as perioperative therapy for locally resectable advanced gastric/gastroesophageal junction adenocarcinoma: study protocol for a prospective, single-arm, phase II clinical trial
by: Xiangyu Meng, et al.
Published: (2025-07-01)

Atezolizumab Plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Real-World Experience From a US Community Oncology Network
by: Cosgrove D, et al.
Published: (2025-04-01)

Real world effectiveness of chemotherapy plus bevacizumab with immunotherapy in colorectal cancer
by: Zhao Gao, et al.
Published: (2025-08-01)

Cryosurgery for radical gastropancreatoduodenal resections in patients with stage IB–IIA pancreatic head cancer
by: M. D. Khanevich, et al.
Published: (2025-06-01)

Biomarker, efficacy and safety analysis of transcatheter arterial chemoembolization combined with atezolizumab and bevacizumab for unresectable hepatocellular carcinoma
by: Shaobo Zhang, et al.
Published: (2025-05-01)

Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ [Clin Mol Hepatol 2024;30:807-823]
by: Sun Young Yim, et al.
Published: (2025-04-01)

Efficacy and safety of perioperative sintilimab plus platinum-based chemotherapy for potentially resectable stage IIIB non-small cell lung cancer (periSCOPE): an open-label, single-arm, phase II trialResearch in context
by: Xiangyang Yu, et al.
Published: (2025-01-01)

Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial
by: Xiaoyang Hong, et al.
Published: (2025-02-01)

Alternating modified CAPOX/CAPIRI plus bevacizumab in untreated unresectable metastatic colorectal cancer: a phase 2 trial
by: Sheng Li, et al.
Published: (2024-12-01)

Neoadjuvant sintilimab and chemotherapy for resectable esophageal squamous cell carcinoma: a phase II clinical trial
by: Jincheng Guo, et al.
Published: (2025-04-01)

Cost-effectiveness of atezolizumab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in the US and Chinese setting: a modelling comparison study
by: Lei Wang, et al.
Published: (2025-03-01)

Perioperative sintilimab and neoadjuvant anlotinib plus chemotherapy for resectable non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 2 trial (TD-NeoFOUR trial)
by: Hongtao Duan, et al.
Published: (2024-10-01)

Aumolertinib plus bevacizumab for untreated advanced NSCLC with EGFR sensitive mutation
by: Lingping Kong, et al.
Published: (2025-06-01)

Use of sintilimab in primary adenosquamous carcinoma of the liver results in pathological complete response: a case report and literature review
by: Zhiqing Bai, et al.
Published: (2025-04-01)

Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study
by: Yan Wang, et al.
Published: (2022-03-01)